Viimeisimmät artikkelit
- Desentum raises €28 million to develop safer, more effective allergen immunotherapy
- New peer-reviewed publication on Desentum’s investigational birch pollen allergen immunotherapy DM-101PX
- Desentum to present at the 2026 EAACI annual congress in Istanbul this week
- Desentum’s 18 M€ share issue from private investors and family offices breaks a record for unlisted growth companies in Finland
- New scientific discovery about the molecular mechanism of allergic reaction sheds light on the severity of peanut allergy
Viimeisimmät kommentit
No comments to show.